On May 30, the European Commission granted marketing authorization for FLIXABI,® an infliximab biosimilar developed by Samsung Bioepis, the joint venture between Biogen and Samsung Biologics. See here for press coverage.
The post EU Approves Samsung Bioepis Infliximab Biosimilar appeared first on Big Molecule Watch.